Abstract
The trifluoro analogue 1 of Casodex® was synthesized in racemic form, according to a strategy based on the use of trifluoropyruvate as a key starting material. This compound showed significant in vitro antiproliferative activity on the human prostate cancer cell line LNCaP.
Keywords: prostate cancer, anti-androgen, trifluoro-casodex analogue, nucleophilic reagents, chromatography
Letters in Organic Chemistry
Title: Synthesis and in Vitro Anti-Proliferative Activity of Racemic Trifluoro-Casodex® (Bicalutamide)
Volume: 2 Issue: 5
Author(s): M. Sani, F. Viani, M. Binda, N. Zaffaroni and M. Zanda
Affiliation:
Keywords: prostate cancer, anti-androgen, trifluoro-casodex analogue, nucleophilic reagents, chromatography
Abstract: The trifluoro analogue 1 of Casodex® was synthesized in racemic form, according to a strategy based on the use of trifluoropyruvate as a key starting material. This compound showed significant in vitro antiproliferative activity on the human prostate cancer cell line LNCaP.
Export Options
About this article
Cite this article as:
Sani M., Viani F., Binda M., Zaffaroni N. and Zanda M., Synthesis and in Vitro Anti-Proliferative Activity of Racemic Trifluoro-Casodex® (Bicalutamide), Letters in Organic Chemistry 2005; 2 (5) . https://dx.doi.org/10.2174/1570178054405850
DOI https://dx.doi.org/10.2174/1570178054405850 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Quinoline-based Protein–protein Interaction Inhibitors of LEDGF/p75 and HIV Integrase: An In Silico Study
Current Topics in Medicinal Chemistry Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry A Short Exploration of Selected Sensitive CYP3A4 Substrates (Probe Drug)
Drug Metabolism Letters HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Ultrasonic and Microwave Assisted Synthesis of Nitrogen-Containing Derivatives of Juglone as Potential Antibacterial Agents
Letters in Organic Chemistry Towards Small Molecule Labelling with 99mTc
Current Radiopharmaceuticals Editorial [Hot topic: (Part I) Recent Trends in Anti-Cancer Drug Discovery (Guest Editor: Fazlul H. Sarkar)]
Mini-Reviews in Medicinal Chemistry A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets MicroRNAs as Cancer Biomarkers
MicroRNA Natural Products as Anti-Invasive and Anti-Metastatic Agents
Current Medicinal Chemistry Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Editorial [Hot Topic: GHRH Analogs and Cancer (Guest Editor: Hippokratis Kiaris )]
Combinatorial Chemistry & High Throughput Screening From the RB Tumor Suppressor to MCR Peptides
Protein & Peptide Letters Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry